This allows modelers to complete their analysis and scientific exploration in real time. Phoenix can also combine the two approaches, enabling models to be run in parallel and on multiple cores, reducing model run time by 80-90%.
Scientists can now use computation grids with hundreds of processors to get their analysis done in a fraction of the time. It also permits within model parallel action so the analysis work for one model can be divided between several CPUs. It supports between model parallelizing, allowing two models to be run together on different processors. Phoenix NLME 8.0 takes advantage of grid computing in several ways.
WINNONLIN MODELING SOFTWARE
It has been only 12 months since the last Phoenix release, and we have added several important new features to the software to allow key drug development decisions to be made quicker,” said David Munro, President of Phoenix Technologies at Certara. “Phoenix is considered the gold standard in PK/PD modeling and simulation, and we take our responsibility to deliver continuous improvement and innovation very seriously. This enables safe and effective new therapeutics to advance more efficiently through the different stages of clinical trials,” said US FDA Commissioner Scott Gottlieb, M.D. “Modeling and simulation play a critical role in organizing diverse data sets and exploring alternate study designs. Phoenix is also employed by many global regulatory agencies for submittal review, including 11 divisions of the FDA.
Phoenix is used by 6,000 researchers at 1,500 biopharmaceutical companies and academic institutions in 60 countries. Included in this Phoenix rollout are Phoenix WinNonlin 8.0, Phoenix NLME 8.0, Phoenix Validation Suite 8.0 and Phoenix in vitro-in vivo correlation (IVIVC) Toolkit 8.0. Phoenix is the most advanced, intuitive, and widely-used software for pharmacokinetic (PK), pharmacodynamic (PD) and toxicokinetic (TK) modeling and simulation. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.Certara, a global provider of model-informed drug development and regulatory science, announced the launch of Phoenix 8.0. This year’s competition received entries from 17 countries/regions, and they were evaluated by a judging panel that included nearly 40 well-respected industry professionals across the globe.Ĭertara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Furthermore, results from the model have been presented by companies developing COVID-19 vaccines at the American College of Clinical Pharmacy (ACCP) and American Association of Pharmaceutical Scientists (AAPS) as well as to global regulatory agencies, including the US FDA.Įstablished in 1963, the R&D 100 Awards program is an annual, worldwide competition held by R&D World magazine that identifies new commercial products, technologies and materials for their technological significance, covering diverse industry sectors. Certara calibrated its model using COVID-19 vaccine structures and validated it by replicating the published clinical data. Its prediction that the optimal timing between the first two COVID-19 vaccine doses is eight weeks was validated by the Pitch study conducted at Oxford University.
WINNONLIN MODELING SIMULATOR
We are also now applying our Vaccine Simulator to develop vaccines for oncology and respiratory syncytial virus.”Ĭertara’s Simcyp COVID-19 Vaccine Model has demonstrated that it can accurately predict the outcomes of actual clinical trials using COVID-19 vaccines. “Our COVID-19 Vaccine Model is being used to determine optimal vaccine doses and timing between doses, investigate differences in immune response with age and ethnicity, evaluate the duration of immune response after vaccination, and identify the best booster sequencing for COVID-19 vaccines. “We are proud and honored that the R&D 100 Awards judges recognized the important contributions being made by Certara’s biosimulation software during this pandemic,” said Piet van der Graaf, PharmD, PhD, senior vice president of Quantitative Systems Pharmacology at Certara. The model, which is incorporated in Certara’s Vaccine Simulator, has been used by major pharmaceutical companies and allows researchers to study how a vaccine is handled by the human body in computer-generated, virtual populations. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in science and technology” in the past year. 25, 2021 (GLOBE NEWSWIRE) - Certara, Inc.
WINNONLIN MODELING PDF
PDF Version Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category
0 kommentar(er)
